MW151 and HA-WBRT in Patients With Brain Metastases
Status:
Not yet recruiting
Trial end date:
2024-08-14
Target enrollment:
Participant gender:
Summary
HYPOTHESIS: MW151 intervention will attenuate radiation induced cognitive impairment caused
by hippocampal-avoidant whole brain radiation therapy (HA-WBRT) for brain metastases.
RATIONALE: There is non-clinical evidence that MW151 reduces brain inflammation and improves
neurocognitive outcomes in animal models of radiation therapy induced cognitive dysfunction,
and in animal models of other CNS disorders.
PURPOSE: This feasibility trial will study MW151 as a mitigator of cognitive dysfunction
caused by HA-WBRT in adult patients with brain metastases from solid tumors, as compared with
a control group of patients receiving HA-WBRT and placebo.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoChem Therapeutics, LLC
Collaborators:
National Cancer Institute (NCI) Northwestern Medicine